Skip to content

The comparison of the efficacy of three different treatment protocols on the type 3 chronic prostatitis (chronic pelvic pain syndrome)

Different treatment protocols for chronic prostatitis

Original Research • doi:10.4328/JCAM.10.2.17 • Published: May 1, 2010

Authors

Fikret Erdemir1, Fatih Fırat1, Doğan Atılgan1, Nihat Uluocak1, Bekir Süha Parlaktaş1, Adem Yaşar1
Affiliations

1Department of Urology, Faculty of Medicine, Gaziosmanpaşa University, Tokat, Türkiye.

Corresponding Author

Fatih Fırat

ffrat60@gmail.com

+90 505 795 31 12

Abstract

Aim In this study, the effect of three different treatment protocols on the type 3 chronic prostatitis was evaluated. In addition to our knowledge, the comparative studies which related CPPS are limited in Turkish literature.
MethodsBetween January 2004 and December 2008 a total of 87 male patients with diagnosed of type 3 chronic prostatitis, were evaluated in our clinic. According to treatment protocols patients with type 3 chronic prostatitis, were randomized into three groups as fallows group 1; antibiotic+anti-inflammatory+α-blocker, group 2; α-blocker and group 3; antibiotic+anti-inflammatory. Pretreatment and post treatment results were compared.
ResultsThe mean age of all patients was 34.14±7.68 years. The mean age of the patients was 34.13±7.39 years, 34.76±7.99 years, and 33.72±8.25 years in group 1, group 2 and group 3, respectively (p>0.05). While the improvement rates after treatment was detected 68% in group 1, these rates were found as 35.3% and 52% in group 2 and group 3, respectively. This difference was statitistically significant in combined group when compared to other groups (p=0.047).
ConclusionAlthough alternative treatment researches have still been continue in type 3 chronic prostatitis which consist of 90-95% of all prostatitis. It is seen that combined treatment is beneficial. However, studies in larger, randomized and controlled series are needed to prove the effect of treatment on type 3 chronic prostatitis.

Keywords

prostatitis chronic pelvic pain syndrome treatment antibiotic alfa-blocker

Declarations

Additional Information

Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.

Rights and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/

View full license details →

About This Article

Received:
October 11, 2009
Accepted:
December 11, 2009
Published Online:
May 1, 2010
Printed:
May 1, 2010